SynGenis raises $4M pre-IPO to build integrated genetic-medicine platform
What's the deal? SynGenisDealroom has a profile for this one. Try Dealroom →, a Perth-based biotech, has completed an oversubscribed A$4 million ($2.8 million) pre-seed raise to fund an AI-driven platform for developing RNA and DNA-based medicines. The round drew sophisticated investors through Euroz HartleysDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Rather than backing a single drug candidate, SynGenis is building six connected divisions to take genetic medicines from computer-generated concepts through to clinical-grade manufacturing under one roof. At its core sits Discovery AI, a system that identifies therapeutic targets, designs RNA and DNA candidates, and screens them computationally.
Why now? The company frames the raise as a pre-float step ahead of a planned listing. "By the time we reach a listing the market is looking at a diversified, integrated platform rather than a single bet," said managing director Thomas Hanly.
SynGenis has specialist expertise in DNA and RNA assay design and oligonucleotide synthesis — short, laboratory-made genetic sequences that switch off harmful genes or target disease-causing pathways. Its research-grade manufacturing business has operated for more than six years and already generates commercial revenue.
Why it matters: The raise sits in the top 10% of seed-stage rounds in Australia by size, based on 3,410 comparable deals. It also aims at a gap SynGenis says has long pushed promising Australian science offshore: the lack of a domestic pathway from discovery to commercial medicine.
The signal: The COVID-19 pandemic turned mRNA from a promising technology into one of healthcare's fastest-growing fields, drawing billions in global investment. SynGenis is betting that owning the full chain — from AI-led discovery to manufacturing — beats specialising in a single link as demand for RNA therapeutics, diagnostics, and specialist manufacturing capacity keeps rising.
Read more: The Sydney Morning Herald
Image credit: SynGenis
